From Vision to Reality: How ARPA-H Plans to Build the SURPASS Clinical Trial Model
Part 2 of a Three-Part Series
Traditional clinical development often relies on separate clinical phases, repeated trial startups, static designs, and duplicated operational infrastructure.
In Part 1 of this series, we explored how Operation TrialBlazer and the Advanced Research Projects Agency for Health (ARPA-H) are addressing these challenges, including through the ARPA-H SURPASS program (Simulation-augmented, Real-time Platform Adaptive Seamless Trials).
SURPASS proposes a new approach to clinical trials: perpetual adaptive platform trials that combine predictive computational models, shared trial infrastructure, common control groups, and real-time analysis to support earlier decision-making as evidence accumulates. This approach could help patients access effective treatments earlier.
Through its SURPASS Innovative Solutions Opening (ISO), ARPA-H is seeking multidisciplinary teams capable of developing and testing the infrastructure needed to pursue this approach.
Understanding the ARPA-H SURPASS Innovative Solutions Opening (ISO)
On September 30, 2026, ARPA-H launched SURPASS to explore whether drugs and biologics can be evaluated faster, at lower cost, and with fewer participants than conventional clinical-development approaches.
Through its Innovative Solutions Opening (ISO), ARPA-H is inviting eligible organizations to propose solutions for developing and clinically validating this new approach. The solicitation, ARPA-H-SOL-26-164, outlines the program’s technical requirements, expectations for multidisciplinary Core Platform Teams, and milestones for evaluating progress.
SURPASS is a five-year research and development program. Its proposed capabilities and intended efficiencies remain to be demonstrated through platform development and clinical validation.
The Three Technical Areas of SURPASS
The ARPA-H SURPASS program focuses on three coordinated technical areas designed to address different challenges in clinical trial development.
Technical Area 1: Phaseless Design Engine
The first technical area focuses on building faster trials with fewer patients.
ARPA-H proposes integrating digital twins and other predictive computational models into clinical trial design. These approaches would allow researchers to simulate clinical and operational outcomes before trial launch and evaluate potential trial designs.
This work also includes developing evidence to support regulatory confidence in predictive modeling approaches.
The goal: Use simulation-informed trial design to help reduce development time and participant burden while maintaining scientific rigor.
Technical Area 2: Continuous Inference Engine
The second technical area focuses on supporting faster decisions as clinical trial evidence accumulates.
SURPASS seeks to enable always-valid, real-time or on-demand analysis to enable faster decision-making as clinical-trial evidence accumulates.
These capabilities are intended to support earlier trial adaptations and reduce reliance on large conventional control groups while maintaining rigorous evidence generation.
The goal: Enable researchers to make earlier, statistically sound decisions about investigational interventions as evidence accumulates.
Technical Area 3: Agentic Operations Layer
The third technical area focuses on reducing the time and cost associated with clinical trial operations.
ARPA-H seeks to develop AI-enabled capabilities that automate key trial startup and operational activities, support the onboarding of new treatment arms, and accelerate data collection, cleaning, and dataset construction.
These capabilities would help research teams manage the operational demands of persistent adaptive platform trials, including changes that occur as trials progress.
The goal: Reduce repetitive operational work and support more efficient clinical trial execution.
What ARPA-H Is Seeking from Multidisciplinary Teams
Developing these capabilities requires expertise across traditionally separate areas of clinical research.
ARPA-H is seeking cross-disciplinary teams with capabilities spanning statistics, artificial intelligence, clinical-trial design, operations, and regulation.
These teams would need to address more than the performance of individual technologies. The proposed trial model depends on bringing design, analysis, and operational capabilities together within shared infrastructure.
For example, an adaptive trial design may support an earlier decision about an investigational intervention. But implementing that decision also requires coordinated clinical operations, appropriate documentation, and continued scientific and regulatory oversight.
This is why integration matters. The technical areas are intended to work together to support a more adaptable clinical-development model.
ARPA-H’s milestone-driven approach also means proposed solutions must demonstrate progress against defined objectives as they are developed and evaluated.
Why Shared Standards and Infrastructure Matter
One of SURPASS’s most significant proposed changes is the use of persistent infrastructure to support multiple investigational interventions.
In conventional clinical development, separate trials may require organizations to repeat activities such as trial startup, operational setup, and data management.
SURPASS explores whether shared platforms could reduce this duplication while maintaining the standards needed for rigorous clinical research.
Looking Ahead: What SURPASS Could Mean for Research Pharmacy
The ARPA-H SURPASS program represents an ambitious effort to rethink how clinical trials are designed, analyzed, and operated.
Its proposed combination of predictive computational models, continuous analysis, and shared operational infrastructure raises important questions about how clinical research organizations can support more adaptive trial designs.
These questions are particularly relevant to investigational drug services, where research pharmacy operations depend on accurate investigational product management, standardized documentation, and coordination across research teams.
As clinical-trial models evolve, research pharmacies may need to consider how their workflows and systems could support increasingly adaptable research operations while maintaining accountability and regulatory compliance.
In Part 3 of this series, we’ll explore the potential implications for research pharmacy, including investigational product accountability, operational workflows, and the capabilities needed to support emerging clinical trial models.
References
Advanced Research Projects Agency for Health. SURPASS: Simulation-augmented, Real-time Platform Adaptive Seamless Trials. SURPASS program page
Advanced Research Projects Agency for Health. HHS Launches SURPASS and New Efforts to Accelerate Faster, Smarter Clinical Trials. September 30, 2026. ARPA-H SURPASS announcement
Advanced Research Projects Agency for Health. Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS), Innovative Solutions Opening ARPA-H-SOL-26-164. September 30, 2026. ARPA-H-SOL-26-164 on SAM.gov
About the Author

Rachael Aletti, Pharm. D.
With over 13 years of experience as a licensed pharmacist, Rachael has worked primarily in academic medical centers, starting in inpatient care and transitioning to Investigational Drug Services in 2013. She graduated Summa Cum Laude from Massachusetts College of Pharmacy, completed a PGY1 Pharmacy Practice Residency at Montefiore Medical Center, and practiced at Montefiore before joining the IDS at NYP-Weill Cornell Medical Center.
Rachael joined McCreadie Group in 2019 as an Account Manager, leading new site implementations, optimizing Vestigo at existing sites, and fostering a collaborative community in investigational drug services. She pioneered the growth of the Research Pharmacy Summit and Vestigo’s Customer Success team before transitioning to Business Development Manager, focusing on new contracts and strategic planning. Now a Solutions Engineer, Rachael combines her technical expertise with deep knowledge of research pharmacy management to understand client needs and showcase Vestigo’s capabilities.